|
EQS-News: Viromed Medical AG
/ Key word(s): Alliance
Viromed Medical AG: Cooperation between relyon plasma GmbH and Viromed Medical GmbH Pinneberg/Regensburg, 5 December 2024 –Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65) is pleased to inform about the cooperation between its subsidiary Viromed Medical GmbH and relyon plasma GmbH, a subsidiary of TDK Electronics AG (link to the original news: https://www.relyon-plasma.com/cooperation-relyon-plasma-gmbh-and-viromed/). relyon plasma GmbH, a subsidiary of TDK Electronics AG, and Viromed Medical GmbH are jointly researching the use of cold atmospheric pressure plasma in medicine. Here, relyon plasma is responsible for developing the technology that utilizes plasma. Within the cooperation, Viromed is responsible for the approval of the device and its distribution. Viromed Medical GmbH has been involved in basic research into viruses and bacteria since 2004 and is revolutionizing medical technology using cold atmospheric plasma in room air purification, wound healing and intensive care medicine. Plasma in dermatology At Arab Health, the global healthcare exhibition in Dubai, from 27th – 30th January 2025, relyon plasma will be presenting the ViroCAP® system from Viromed for the first time in addition to its existing products PiezoBrush PZ3 and MediPlas system. MediPlas RONS generator in infection research As a partner of Viromed, relyon plasma will establish the prototypes for the application and ensure the standardized generation of cold plasma as well as its characterization and consistency in the execution of the tests. Viromed Medical AG holds the exploitation rights. Simona Lerach, Managing Director of relyon plasma GmbH, summarizes the cooperation: “We are delighted to have partnered with Viromed, an innovative company in the medical field that is conducting in-depth research and development into the use of cold atmospheric pressure plasma in medicine with our components.”
About Viromed Medical AG Viromed Medical AG specializes in the development, manufacture and distribution of medical products. The operating business of the company, which has been listed on the stock exchange since October 2022, focuses on the distribution of innovative cold plasma technology for medical applications via its wholly owned subsidiary Viromed Medical GmbH. Viromed can draw on a broad customer base in the DACH region. Viromed Medical AG is pursuing the goal of further advancing the use of CAP in medicine in the coming years and realizing the corresponding growth potential. About relyon plasma GmbH Relyon plasma GmbH, based in Regensburg, Germany, is a subsidiary of TDK Electronics AG. True to its motto "rely on plasma", the company sees itself as a professional supplier of innovative plasma systems and a service provider for customer-specific process solutions. Thanks to many years of professional experience in the industry, relyon plasma offers a wide range of specialized plasma components for manual applications and inline processes. Atmospheric pressure plasma is used to disinfect, clean, modify and functionalize a wide variety of surfaces. The materials can thus be optimally prepared for bonding, painting and printing.
Contact Viromed Medical AG Uwe Perbandt
Contact reylon plasma GmbH relyon plasma GmbH
05.12.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
| Language: | English |
| Company: | Viromed Medical AG |
| Flensburger Straße 18 | |
| 25421 Pinneberg | |
| Germany | |
| Phone: | +49 4101 809960 |
| E-mail: | kontakt@viromed-medical.de |
| Internet: | https://www.viromed-medical-ag.de/ |
| ISIN: | DE000A3MQR65 |
| WKN: | A3MQR6 |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf (Primärmarkt), Frankfurt (Basic Board), Hamburg |
| EQS News ID: | 2044321 |
| End of News | EQS News Service |
|
|
2044321 05.12.2024 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
